Gesynta Pharma AB

Gesynta Pharmas drug candidate vipoglanstat (GS-248) is in clinical phase II development for the treatment of endometriosis a painful, chronic inflammatory disease that affects about 10 percent of women of reproductive age. Endometriosis often leads to severely reduced quality of life, and current drug treatments are inadequate for many patients. Gesynta Pharma aims to exploit the full potential of microsomal prostaglandin E synthase-1 (mPGES-1) as a pharmacological target by developing products in areas of unmet medical need where mPGES-1 inhibition provides clear benefits compared to current therapy. Gesynta Pharmas second drug candidate to reach clinical development, GS-073, has the same...

Endometriosis,anti-inflammatory,mpges-1,arthritis,inflammatory pain,chronic pain,pge2,prostaglandin,women's health,inflammation,karolinska,non-hormonal,disease modification,phase ii,phase 2,linc,hadean,industrifonden,disease-modifying,infertility,and dysmenorrhea

Gesynta pharma ab operates in the Pharmaceutical manufacturing industry.

Gesynta pharma ab's revenue is 1m - 10m

Gesynta pharma ab has 11 - 50 employees.